Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.

The entities involved

• Merck KGaA →

  German multinational science and technology company

  • MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
  • Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Europe →

  terrestrial continent located in north-western Eurasia

  • The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
  • The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49

Related events

• Litigation regarding FDA approval process.Sep 2
• Trinity Biotech announced that its Premier Hb9210™ analyser received FDA clearance and the company plans to accelerate growth across its diagnostics franchise in Europe.Aug 28
• The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.Sep 10
• The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.Sep 17
• OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.Sep 2